Divis Laboratories Ltd Stock Price Today (NSE: DIVISLAB)
Fundamental Score
Divis Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Divis Laboratories Ltd share price today is ₹6912.00, up +1.13% on NSE/BSE as of 22 May 2026. Divis Laboratories Ltd (DIVISLAB) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.70L (Cr). The 52-week high for DIVISLAB share price is ₹7071.50 and the 52-week low is ₹5636.50. At a P/E ratio of 68.59x, DIVISLAB is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.35% and a debt-to-equity ratio of 0.01.
Divis Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Divis Laboratories Ltd share price chart: 10.06% return over the past month. 52-week high ₹7071.50, 52-week low ₹5636.50.
Divis Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹6850.00 | ₹6942.00 | ₹6835.50 | ₹6912.00 | 3.22L (Cr) | |
| ₹6750.50 | ₹6868.00 | ₹6658.00 | ₹6835.00 | 3.40L (Cr) | |
| ₹6920.50 | ₹6968.00 | ₹6732.00 | ₹6760.50 | 3.21L (Cr) | |
| ₹6830.00 | ₹6948.00 | ₹6817.00 | ₹6921.50 | 4.24L (Cr) | |
| ₹6680.00 | ₹6870.00 | ₹6643.00 | ₹6796.00 | 5.14L (Cr) | |
| ₹6710.00 | ₹6745.00 | ₹6636.00 | ₹6644.00 | 1.56L (Cr) | |
| ₹6700.00 | ₹6785.00 | ₹6650.00 | ₹6714.00 | 1.97L (Cr) | |
| ₹6700.00 | ₹6759.00 | ₹6675.00 | ₹6710.50 | 1.55L (Cr) | |
| ₹6705.00 | ₹6780.00 | ₹6683.00 | ₹6702.50 | 3.30L (Cr) | |
| ₹6690.00 | ₹6765.50 | ₹6615.50 | ₹6702.00 | 3.14L (Cr) |
Divis Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹6508.00 | ₹6968.00 | ₹6483.50 | ₹6912.00 | +6.21% | |
| ₹6002.00 | ₹6549.50 | ₹5647.50 | ₹6502.50 | +8.34% | |
| ₹6271.50 | ₹6479.00 | ₹5901.50 | ₹5947.00 | -5.17% | |
| ₹6056.00 | ₹6793.00 | ₹5890.00 | ₹6408.50 | +5.82% | |
| ₹6398.00 | ₹6731.50 | ₹5955.00 | ₹6051.00 | -5.42% | |
| ₹6500.50 | ₹6598.00 | ₹6265.00 | ₹6392.50 | -1.66% | |
| ₹6738.00 | ₹6904.50 | ₹6322.00 | ₹6477.00 | -3.87% | |
| ₹5692.50 | ₹6775.00 | ₹5675.00 | ₹6738.00 | +18.37% | |
| ₹6131.50 | ₹6280.00 | ₹5636.50 | ₹5689.50 | -7.21% | |
| ₹6598.00 | ₹6598.00 | ₹5856.50 | ₹6131.50 | -7.07% | |
| ₹6828.50 | ₹7071.50 | ₹6473.00 | ₹6595.50 | -3.41% | |
| ₹6614.50 | ₹6862.50 | ₹6455.50 | ₹6809.50 | +2.95% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Divis is an API pure play trading at nosebleed valuations; execution needs to be flawless.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Divis Laboratories' stock has shown mixed performance recently. On April 2, 2026, the stock was down 1.39% to , marking its fifth straight session of decline. However, the stock had jumped 1.07% in the past year, outperforming the NIFTY. Recent news indicates that the company has scheduled its Q4 FY26 results for May 15, 2026.
CORE STORY (THE REAL GAME)
Divis is an API powerhouse, and the real game is its ability to capitalize on custom synthesis and generic API opportunities, especially with the expected entry of GLP-1 drugs and increased revenues from contrast media products.
- GLP-1 drug opportunity in 2026
- Strong custom synthesis growth
- Robust export growth
- Positive Q4 FY26 results
- Constructive FY27 guidance
- New long-term manufacturing agreements
- High valuation
- Concentration in a few molecules
- US generics pricing pressure
FII decreased by 0.35%, DII increased by 0.72% [cite: brief]
Indian pharma industry is projected to reach $130 billion by 2030, driven by expanding global demand and innovation.
Yes, Free Cash Flow 5Y: ₹4695.21 Cr [cite: brief]
Divis's near-term performance hinges on Q4 results and FY27 guidance. Success in GLP-1 drugs and custom synthesis will be key to sustaining growth.
Primary Thesis Risk
Failure to capitalize on GLP-1 drug opportunities and custom synthesis growth.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Divis Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Divis Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DIVISLAB across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (15.35%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.44%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (34.98%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (35.10%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (16.12%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (270.58x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹4695.21 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.89%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 39.07%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 68.59x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Divis Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Divis Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Divis Laboratories LtdDivis Laborator...Selected✓ DIVISLAB • 532488 | 67.9/100 | ₹6912.00₹6912 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1409.80₹1410 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1512.80₹1513 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5470.00₹5470 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 65/100 | ₹27795.00₹27795 | ₹63358.16₹63358.16 | 41.99Average 42.0 Average | 35.68%Excellent 35.68% Excellent | 46.25%Excellent 46.25% Excellent | 0.05Excellent 0.1 Excellent | 18.98%Excellent 18.98% Excellent | 9.38%Good 9.38% Good | 1.59% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
- Lupin Ltd share price95148.15 Cr
Divis Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for DIVISLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹82.53 | ₹6392.50 | 77.5x |
| FY 2024 | ₹60.27 | ₹6098.80 | 101.2x |
| FY 2023 | ₹68.69 | ₹3903.90 | 56.8x |
| FY 2022 | ₹111.52 | ₹3413.20 | 30.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Divis Laboratories Ltd Dividend History
Annual cash dividends paid by DIVISLAB — dividend yield 0.47%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹796.00 Cr |
| FY 2024 | ₹796.00 Cr |
| FY 2023 | ₹796.00 Cr |
| FY 2022 | ₹530.94 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Divis Laboratories Ltd Quarterly Performance
Latest quarterly metrics for DIVISLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
16.12%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
35.10%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.65%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
10.41%
Compounded annual net profit growth over 5 years
Divis Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DIVISLAB — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Divis Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Divis Laboratories Ltd (DIVISLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Divis Laboratories Ltd
About DIVISLAB (Divis Laboratories Ltd)
Divis Laboratories Ltd is a prominent global pharmaceutical player, distinguished by its robust manufacturing capabilities and commitment to quality. As a leading manufacturer, the... company specializes in the production of active pharmaceutical ingredients (APIs), intermediates, and a diverse range of specialty chemicals. Divis is strategically positioned to meet the demands of the pharmaceutical industry across the world, adhering to stringent regulatory standards in key markets like North America, Europe, and Asia. Leveraging advanced technology and a highly skilled workforce, Divis operates state-of-the-art facilities focused on enhancing production efficiency and quality control. The company's focus on innovation and sustainability has enabled it to establish long-term partnerships with some of the largest pharmaceutical companies. Beyond its core API and intermediate business, Divis Laboratories Ltd has also diversified into custom manufacturing and synthesis, offering tailored solutions to meet specific client needs. The company's expertise in complex chemical processes and its agile manufacturing infrastructure make it an ideal partner for pharmaceutical companies seeking to outsource production or develop new chemical entities. Divis's custom synthesis capabilities support both early-stage research and development as well as commercial-scale manufacturing. This adaptability strengthens its position as a reliable and innovative solutions provider. The company's unwavering dedication to quality and customer satisfaction further fosters long-term relationships and drives sustained growth. Divis Laboratories Ltd also produces a range of nutraceutical ingredients that add considerable value to the company. These ingredients cater to a variety of consumer segments, including dietary supplements, food, and beverage industries. Divis is committed to research and development of value added products and continues to expand its portfolio. They are dedicated to meeting the increasing demand for health and wellness products.
Company Details
Key Leadership
Corporate Events
DIVISLAB Share Price: Frequently Asked Questions
What is the current share price of Divis Laboratories Ltd?
Divis Laboratories Ltd (DIVISLAB) trades at ₹6912.00 on NSE and BSE. Market cap ₹1.70L (Cr). Educational data only.
What is the P/E ratio of Divis Laboratories Ltd?
Divis Laboratories Ltd has a P/E of 68.59x vs industry average 31.77x.
What is the Bull Run score for Divis Laboratories Ltd?
Divis Laboratories Ltd has a Bull Run score of 67.9/100 based on 25+ financial parameters.
Does Divis Laboratories Ltd pay dividends?
Divis Laboratories Ltd has a dividend yield of 0.47%. Past dividends don't guarantee future payments.
What is the ROE of Divis Laboratories Ltd?
Divis Laboratories Ltd has ROE of 15.35%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Divis Laboratories Ltd?
Divis Laboratories Ltd has debt-to-equity of 0.01.
Is Divis Laboratories Ltd a good investment?
Bull Run gives Divis Laboratories Ltd a score of 67.9/100. This is not investment advice — consult a SEBI-registered advisor.